JUBILANT PHARMOVA LTD

In the earnings webinar held on May 22, 2026, management reported a 19% year-on-year revenue growth for Q4 FY2026, reaching Rs.2,290 Crores, driven by increases in radiopharma, allergy immunotherapy, CDMO sterile injectables, and generics. EBITDA rose by 2% to Rs.363 Crores, although the EBITDA margin decreased by 272 basis points to 15.7% due to supply shortages in Radiopharmaceuticals. For the full year FY2026, revenue grew by 14% to Rs.8,280 Crores, with EBITDA increasing by 8% to Rs.1,326 Crores. Management noted that normalized PAT for the year grew by 7% to Rs.442 Crores. The discussion included insights on production challenges at CMO Montreal and the anticipated stabilization of EBITDA margins in H2 FY2027. Management also highlighted ongoing investments in manufacturing capacity and the strategic focus on high-value biologics.

The document presented a balanced view of growth and challenges faced by the company.